TET1 and cancer: Upregulated TET1 acts as an oncogene, leading to the hypomethylation and activation of cancer‐specific oncogenic signaling pathways (including phosphoinositide 3‐kinase [PI3K], epidermal growth factor receptor [EGFR], and platelet‐derived growth factor), which results in the development of TNBC [258, 260].